Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
Condition: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
MeSH terms: Uterine Cervical Neoplasms
Intervention: simlukafusp alfa; Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Gemcitabine; Vinorelbine
Intervention description: simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.; Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.; Single-agent treatment administered as per approved protocol.; Single-agent treatment administered as per approved protocol.
Intervention MeSH terms: Gemcitabine; Atezolizumab; Vinorelbine; Antibodies
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 256.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor
      activity of simlukafusp alfa in combination with atezolizumab in participants with advanced
      and/or metastatic solid tumors. Currently the focus is on participants with Head and Neck,
      oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants who have progressed on at least one previous regimen of anticancer
             therapy (chemotherapy, mutation targeted therapy, and/or CPI therapy)

          -  Measurable disease, as defined by RECIST Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 or Karnofsky
             Performance Score greater than or equal to (>=) 70

          -  Life expectancy of >=12 weeks

          -  Confirmed at least one tumor lesion with location accessible to safely biopsy per
             clinical judgment of the treating physician.

        Biopsies are not applicable to participants in Cohorts G, H, K, and L presenting with a
        single target lesion and absence of any non-target lesion.

          -  Consent to provide an archival tumor tissue sample (if available, applicable to all
             participants)

          -  Willingness to undergo baseline and on-treatment tumor biopsies for pharmacodynamics
             (PD) biomarker analysis (biopsies are optional for Cohort A)

          -  Adequate cardiovascular function as defined in the study protocol

          -  AEs related to any previous radiotherapy, chemotherapy, or surgical procedure must
             have resolved to Grade less than or equal to (<=) 1, except alopecia (any grade) and
             Grade 2 peripheral neuropathy

          -  Adequate haematological, liver, and renal functions.

          -  Participants with unilateral pleural effusion (indications other than NSCLC) are
             eligible if they fulfill both of the following:

               1. NYHA Class 1

               2. Forced expiratory volume 1 (FEV1) and forced vital capacity (FVC) >70% of
                  predicted value; participants with lung metastases should present with DLCO >60%
                  of predicted value.

          -  Participants with Gilbert's syndrome will be eligible for the study

          -  Participants must have had confirmed diagnosis of recurrent or metastatic squamous
             cell carcinoma head and neck, or esophageal cancer or metastatic, persistent or
             recurrent squamous cervical cancer.

        Exclusion Criteria:

          -  Symptomatic or untreated central nervous system (CNS) metastases

          -  History of treated asymptomatic CNS metastases as described in the protocol

          -  Spinal cord compression not definitively treated with surgery and/or radiation or
             previously diagnosed and treated spinal cord compression without evidence that disease
             has been clinically stable for >=2 weeks before enrollment

          -  Leptomeningeal disease

          -  An active second malignancy

          -  Penetrating tumor infiltration

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results

          -  Episode of significant cardiovascular/cerebrovascular acute disease within 6 months
             before study treatment administration

          -  History of significant vascular disease (for example, aortic aneurysm, aortic
             dissection)

          -  Active or uncontrolled infections

          -  Human immunodeficiency virus (HIV) or Active Hepatitis A, B, C, D or E infection
             (HAV/HBV/HCV/HDV/HEV).

          -  Severe infection within 4 weeks before study treatment administration including, but
             not limited to, hospitalization for complications of infection, bacteremia, or severe
             pneumonia.

          -  History of chronic liver disease or evidence of hepatic cirrhosis

          -  Dementia or altered mental status that would prohibit informed consent

          -  History of, active or suspicion of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced),
             organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia,
             etc.), or evidence of active pneumonitis on screening chest computed tomography (CT)
             scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted

          -  Bilateral pleural effusion confirmed by X-ray

          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that give reasonable suspicion of a disease or condition that would
             contraindicate the use of an investigational drug

          -  Concurrent therapy with any other investigational drug

          -  Immunomodulating agents as described in study protocol

          -  Chronic use of steroids

          -  Last dose with any cytostatic treatments < 28 days before study treatment
             administration

          -  Radiotherapy within the last 4 weeks before start of study treatment administration,
             with the exception of limited field palliative radiotherapy

          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or at
             any time during the study and 5 months after the last dose of atezolizumab

          -  Major surgery or significant traumatic injury <28 days before study treatment
             administration (excluding fine needle biopsies) or if wound healing has not completed
             after surgery or anticipation of the need for major surgery during study treatment

          -  Known hypersensitivity to any of the components of the simlukafusp alfa drug product
             or atezolizumab drug product

          -  Severe dyspnea at rest or requiring supplementary oxygen therapy Locally curative
             options are available for participant's disease.